

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/067942 A1

(51) International Patent Classification⁷: **A61K 31/726**,
38/39, A61P 19/02, 19/04, 37/02

(21) International Application Number:
PCT/AU2005/000044

(22) International Filing Date: 14 January 2005 (14.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2004900250 16 January 2004 (16.01.2004) AU

(71) Applicant (for all designated States except US): **INSTITUTE OF NUTRACEUTICAL RESEARCH PTY LTD** [AU/AU]; 27/9 Powells Road, Brookvale, NSW 2100 (AU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GHOSH, Peter** [AU/AU]; 69 Lauderdale Avenue, Fairlight, NSW 2094 (AU).

(74) Agent: **F B RICE & CO**; 605 Darling Street, Balmain, NSW 2041 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **GLYCOSAMINOGLYCAN PEPTIDES DERIVED FROM CONNECTIVE TISSUES AND USE THEREOF IN THE PREVENTION OF ARTHRITIS AND OTHER DEGENERATIVE MEDICAL CONDITIONS**

(57) Abstract: The inventors sought to provide compositions and methods of prophylaxis to prevent these harmful immune responses in patients and to prevent the related undesirable symptoms biological tissue such as for example inflammation, cell injury, tissue injury, tissue degradation, tenderness, redness, joint stiffness, joint swelling, restricted mobility and reduced strength. The inventors found that prophylactic therapy of an animal comprising administering a pharmaceutical composition comprising a GAG-peptide complex, optionally together with a connective tissue derived polypeptide, prevented the onset of at least one undesirable symptom.



WO 2005/067942 A1